Kapstone India Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-01-2025
- Paid Up Capital ₹ 0.10 M
as on 07-01-2025
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2017)
- Profit -408.58%
(FY 2017)
- Net Worth -29.69%
(FY 2017)
- Total Assets -21.48%
(FY 2017)
About Kapstone India Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sunita Kendre, Ankush Ramrao, and Lav Ramrao serve as directors at the Company.
- CIN/LLPIN
U24233MH2015PTC266129
- Company No.
266129
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jun 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kapstone India Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunita Kendre  | Director | 30-Jun-2015 | Current |
| Ankush Ramrao | Director | 30-Jun-2015 | Current |
| Lav Ramrao | Director | 30-Jun-2015 | Current |
Financial Performance of Kapstone India Pharmaceuticals.
Kapstone India Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 408.58% decrease in profit. The company's net worth observed a substantial decline by a decrease of 29.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Kapstone India Pharmaceuticals?
In 2017, Kapstone India Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Capstone India Beverages Private LimitedActive 9 years 6 monthsSunita Kendre, Ankush Ramrao and 1 more are mutual person
- Neu Medix Healthcare India Private LimitedActive 14 years 10 months
Sunita Kendre, Ankush Ramrao and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kapstone India Pharmaceuticals?
Unlock and access historical data on people associated with Kapstone India Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kapstone India Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kapstone India Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
